{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6ada04190a858cda44791c11?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?","description":"<p>The Lymphoma Hub was pleased to speak with Ulrich Jäger, Medical University of Vienna, AT. We asked, How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL? </p><p><br></p><p>In this interview, Jäger discusses the potential role of CD19/CD20-targeted chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). He explores the rationale for targeting both CD19 and CD20, highlights clinical data with zamtocabtagene autoleucel, and considers how tandem CAR T-cell therapies may address unmet needs in R/R LBCL. Finally, he discusses how these approaches may fit into the future treatment landscape for patients with LBCL. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</p>","author_name":"Scientific Education Support"}